Proscia

A digital pathology platform with AI built into it rather than an AI product, and the company is deliberate about that framing. Concentriq is first an image management and workflow system for whole slide pathology, which is what high volume labs buy. The AI layer is real and increasingly native, recommending stain panels and ancillary tests from what it sees in tissue and scoring image analysis biomarkers including PD-L1, HER2, and Ki-67 in the viewer, with the company describing an AI native architecture and domain specific vision, language, and multimodal models. The platform retains value without the AI; the AI does not exist without the platform.

Explicitly built around expert verification, and the company argues the position publicly rather than just implementing it. Outputs are described as backed by spatial, contextual, and quantitative evidence, transparent and interpretable and built for expert verification, with intelligence woven into high judgment workflows designed for experts in the loop. In practice the pathologist reviews AI recommended stain panels and adjusts inline, and can modify regions of interest on biomarker scoring with results updating in real time. The company's CEO has publicly challenged the replacement narrative, arguing the opportunity is eliminating administrative burden rather than diagnostic expertise, which is consistent with how the product is scoped.

The architecture is described specifically as domain specific vision, language, and multimodal models reasoning across images and data, with images, metadata, and clinical context unified in one layer. Early validation practice was strong and disclosed: its dermatopathology classifier was validated in a multi site study across named academic and commercial laboratories using more than 20,000 patient biopsy slides. Falls short of an A because current model performance figures and validation methodology for the shipping AI features are not published at that same level of detail.

Regulatory clearance for primary diagnosis is the anchor, supported by earlier multi site algorithm validation across more than 20,000 biopsy slides at named institutions including two university hospitals and two commercial dermatopathology laboratories. Deployment spans high volume diagnostic laboratories and large life sciences R&D organizations. What is less visible publicly is quantified operational outcome data, meaning turnaround time, error reduction, or throughput figures from deployed customers, which the company references qualitatively rather than with numbers.

No published PHI framework or data governance disclosure was located. The platform holds whole slide images with associated clinical metadata for both diagnostic laboratories and pharmaceutical research customers, and the boundary between those two data environments is a question a buyer should raise explicitly.

No HIPAA or BAA statement was located in public materials, though business associate status is structurally required for a vendor hosting diagnostic images for clinical laboratories.

No SOC 2, HITRUST, or ISO 27001 attestation was located. The company does state the research platform is GxP ready for life sciences research, which is a regulated quality framework rather than an information security attestation, and is meaningful to pharmaceutical customers for a different reason. A buyer should not read GxP readiness as covering security.

Cleared for primary diagnosis, which is the highest bar in digital pathology, and the company draws the boundary with unusual discipline. Concentriq AP-Dx is FDA 510(k) cleared in the United States and CE-IVDR marked in the EU for primary diagnosis. Critically, the company states plainly that the separate research edition is a Research Use Only product not for use in clinical diagnosis, and directs clinical buyers to the cleared edition instead. Publishing that distinction prominently rather than blurring it is exactly the practice the index's pathology category calls for, since Research Use Only is a permitted use restriction that vendors frequently obscure.

No formal governance program was located, but the transparency posture is substantive: outputs are stated to be interpretable and evidence backed with granular overlay tools letting pathologists confirm results visually, and the early validation deliberately spanned four independent laboratories rather than a single site. No published analysis addresses performance variation across scanner platforms, staining protocols, or patient demographics, which are the known drift sources in computational pathology.

Integration is with the laboratory information system rather than the chart, which is the correct surface. The company states that AI recommended ancillary test requests flow back into the LIS rather than a separate ticket queue, which is a real workflow closure rather than a display feature. The platform also serves as a host environment for third party algorithms, with at least one external spatial biology vendor embedding its predictive biomarker technology into Concentriq. No named LIS integrations or standards were enumerated.

No hosting, tenancy, or data residency terms were located. Whole slide imaging generates very large data volumes, so storage architecture and location are practical questions a buyer must resolve, and neither is published.

No published pricing. Two distinct editions exist, a cleared diagnostic product for clinical laboratories and a research use product for life sciences, which almost certainly carry different commercial structures, and neither is disclosed.

Two distinct customer bases served by two editions: high volume clinical diagnostic laboratories using the cleared product for primary diagnosis, and life sciences R&D organizations using the research edition for biomarker discovery and clinical trials. Dermatopathology is the evident depth given the validated classifier and derm specific workflow features such as automatic slide orientation, with biomarker scoring extending into oncology. This is a laboratory product; it has no provider or hospital clinical workflow surface.